Vaccine

Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine
Pfizer Shares Are Down Today: What's Going On?
Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine
Pfizer Shares Are Down Today: What's Going On?
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine

Vaccine Recent News

Amid Rapidly Rising Bird Flu Cases, Moderna Lands $176M Worth US Government Contract For Vaccine
The funds will be utilized to finalize the late-stage development and testing of a pre-pandemic mRNA-based vaccine against H5N1 avian influenza.
|
Groundbreaking Fentanyl Vaccine Being Developed To Prevent Fatal Overdoses, Startup Secures $10M
The initiative focuses on commercializing academic research aimed at preventing deadly fentanyl from reaching the brain.
|
AstraZeneca Pulls Plug On Vaxzevria COVID-19 Vaccine Amid Surplus of Updated Vaccines
It is worth noting that AstraZeneca has previously conceded in court documents that Vaxzevria can induce side effects such as blood clots and low blood platelet counts.
|
Marjorie Taylor Greene Faces Democratic Criticism Over 'Vulgarity' And 'Conspiracy' In Vaccine Hearing
Greene, who is not a medical professional, claimed to have a "Ph.D. in recognizing bullshit" during a hearing on vaccine safety and public trust in vaccinations.
|
With Healthier Finances, Clover Bio Shifts To Flu And RSV Vaccines
Key Takeaways: Clover Biopharmaceuticals posted a surge in first-half earnings after a $384 million grant for Covid vaccine development was belatedly folded into its accounts The company has turned its attention to flu vaccines after being hit by waning demand in the crowded Covid market By Molly Wen
|
Meet Eris, The COVID Variant Behind A Summer Resurgence In Cases: 3 Drugmakers Prep Fall Booster Shots
|
FDA Approves New Technique To Extend Supply Of Monkeypox Vaccine: Report
A plan to extend the limited supply of monkeypox vaccine in order to provide additional doses has been approved by the Food and Drug Administration.
|
FDA Eyes New Vaccine Composition In Response To COVID Mutations: Here's What You Need To Know
As COVID-19 continues to mutate and form new variants, the FDA is calling on the major vaccine manufacturers to create a new composition of the vaccine for adults.
|
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
|
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
|
COVID Booster Dose No Longer Required For Employees Of This Tech Giant In US Offices
Meta Platforms Inc (NASDAQ: FB) recently announced that the company no longer requires employees to have COVID-19 booster shots to enter its offices in the U.S. 
|
Is Novavax Turning Around? A Technical Analysis
Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Monday after the company submitted a request to the U.S Food and Drug Administration for Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. Novavax was up 13% at $93.70 Monday afternoon at publication.
|
BofA Downgrades CureVac On Limited 2022 Prospects
There is limited upside from CureVac BV’s (NASDAQ: CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities.
|
What The Future Might Hold For Novavax Stock
Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Thursday after Australia’s national drug regulator granted approval for the company's COVID-19 vaccine. The stock is trading below what traders call a pennant pattern and is showing uncertainty in where it could head next.
|
New Treatments For Opioid Addiction: Vaccine And CBD Product In Development
With drug overdoses having skyrocketed over the past two decades and deaths increased over four times in the period between 1999 and 2017, according to CDC data, it's no surprise that the number of those prone to opioid use disorder and opiate addiction is rising as well.
|
Novak Djokovic Leaves Australia After Losing Visa Appeal; Serbian President Says Aussies 'Humiliated Themselves'
Serbian tennis star Novak Djokovic has left Australia after losing an appeal to stay in the country and seek his tenth Australian Open championship despite being unvaccinated against COVID-19.
|
10 Best Performing S&P 500 Stocks Of 2021
The S&P 500 delivered one of its best years in recent history in 2021, gaining more than 27%. Most U.S. investors had a lot of winners in their portfolios this year, but some stocks certainly performed better than others. Here’s a look at the 10 best-performing stocks in the entire S&P 500 in 2021.
|
Novavax Falls Below Support: What Does This Mean For The Vaccine Stock?
Novavax, Inc. (NASDAQ: NVAX) shares are trading lower Monday, slightly falling below a pattern the stock has been trading in. On Thursday, the company said it expanded a license agreement for its NVX-CoV2373 recombinant nanoparticle protein-based COVID-19 vaccine with SK Bioscience Co.
|

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved